So-Young Business Model Canvas

Collaborations with banks and insurers let So-Young offer medical aesthetic insurance and consumer financing (installments), cutting upfront cost barriers; in 2024 partner-backed loans covered ~38% of procedures, lifting conversion on high-ticket surgeries by ~22%.

So-Young’s key partners—8,000+ certified clinics, 150,000+ influencers, banks/insurers, and OEM suppliers—drive 45% offline GMV, 28% higher conversion via influencer content, 38% of procedures financed, and 12–18% procurement cost savings, while regulatory ties cut enforcement incidents ~30% in 2024.

So-Young runs aggressive digital marketing across Weibo, WeChat, Douyin and Xiaohongshu, targeting men and Gen Z with precision ads, seasonal beauty festivals and subsidy promos that cut first-time booking costs by up to 40%; Q4 2024 campaigns lifted new-user growth 28% vs. prior quarter and reduced CAC (customer acquisition cost) by 18% to ¥130 per user.

Scale app/backend to 10M MAU, 99.95% uptime, 5k RPS, 200TB/mo; target <50ms median API latency and <1% failed teleconsults. Combine AI + 120 moderators to screen 20M reviews/15M photos, cut fraud 92%, run marketing to lower CAC to ¥130 (2024) and lift new-user growth +28% Q4; support 12,000+ providers with analytics for +18% conversion and +22% fill rates.

As one of China’s top medical-aesthetics platforms, So-Young’s brand is a critical intangible asset—its app had ~40 million MAU and platform GMV reached RMB 6.2 billion in 2024, signaling strong consumer trust. The brand’s reputation for transparency and curated professional listings draws premium clinics and wary consumers, helping So-Young enter new provinces and expand services with lower customer acquisition costs and faster clinic onboarding.

So-Young’s key resources: 4.2M before‑after photos and millions of Beauty Diaries (2025 internal), proprietary AI face-scan (1.2M scans in 2024) driving +28% lead-to-consult and +15% AOV, brand with ~40M MAU and RMB 6.2bn GMV (2024), 4,500+ verified clinicians covering 120+ procedures, R&D RMB 200–300m/yr and reserves RMB 1–2bn (2025 est).

So-Young builds community-driven trust by letting users share experiences, ask questions, and give emotional support during aesthetic journeys, which studies show cuts procedure anxiety by ~30% and boosts retention; platforms with active peer support report 20–40% higher lifetime value (LTV). This belonging drives repeat app visits post-procedure, helping So-Young sustain monthly active users (MAU) and increase average revenue per user (ARPU) over time.

So‑Young reduces information asymmetry with 120k+ reviews and 4,500+ providers, raising bookings 18% and cutting adverse events 12% (2025 pilots); it lowers acquisition costs 40–60% via 12M MAU (2025) and drops average procedure prices ~18% through marketplace competition (2024 data).

So-Young’s tiered membership—basic, gold, platinum—offers exclusive discounts up to 20%, priority booking, and dedicated premium support, driving users to centralize aesthetic spend on the platform; in 2024 members accounted for 62% of GMV and had 1.8x higher repeat purchase rates. Loyalty rewards and membership retention raised customer lifetime value by 34% year-over-year, with platinum members contributing 45% of subscription revenue.

So-Young builds social trust via forums, live streams, AI-personalized feeds and tiered memberships, driving 18M MAU (2025), 40% engagement, 28% higher weekly retention, 62% GMV from members, and 34% YoY LTV growth.

So-Young uses Douyin, Little Red Book, and Weibo to funnel users to its app, posting short videos and influencer content that drove an estimated 38% of new installs in 2024; Douyin campaigns alone lifted monthly active users by ~12% in Q3 2024. These third-party channels remain key top-of-funnel drivers, cutting customer acquisition cost by ~18% versus paid search in 2024.

So-Young’s mobile app is the main channel (78% MAU, 64% of RMB 1.2bn GMV in 2024; 12.4 min avg session; 28% discovery→booking). WeChat mini-programs reach WeChat’s 1.3bn users (2024 pilot: bookings/user +28%; onboarding time −40%). Social (Douyin, Xiaohongshu, Weibo) drove ~38% of new installs and cut CAC −18%; events and SEO/SEM added 22% B2B leads and 42% new-user acquisition respectively.

Specialized aesthetic doctors and surgeons use So-Young to build personal brands, showcase portfolios, and manage online reputations; celebrity doctors now drive premium demand—global medical aesthetics spending reached $31.7B in 2024 and China accounted for ~35%, making high-profile practitioners key to customer acquisition and higher-ticket procedures.

Core consumers: Gen Z/Millennials (18–39) = ~62% bookings in 2024; prefer non‑surgical (60% spend) and value reviews. B2B: clinics/hospitals = 35% revenue (ads+SaaS); CAC $120–180. Specialists/celebrity doctors drive higher‑ticket demand; China ≈35% of $31.7B global spend (2024). Male market growing +12% YoY (2024). Investors focus on MAU 3.2M, Q4‑2024 revenue $48.6M, gross margin 62%.

Operating So-Young’s marketplace needs a large workforce across sales, customer support, content moderation, and legal compliance; in 2024 China tech firms paid median annual total compensation of ~RMB 350k–500k per senior staff, so personnel costs likely drive 40–60% of operating expenses. Retention is costly: average tech turnover in China was 20–25% in 2024, pushing recruiting and benefits spend higher across multiple regional hubs.

So‑Young’s biggest costs are user acquisition (~27% of revenue in 2024), personnel (40–60% of Opex; senior pay ~RMB350–500k), R&D (25–30% of Opex; $18–22M estimate in 2024), and compliance (12–18% of Opex; legal costs +22% since 2023); cloud/storage and CDN drive 30–50% YoY cloud cost growth.

So-Young earns recurring revenue by charging clinics subscription fees for its SaaS CRM and clinic-management suite; in 2025 similar med-tech platforms report average ARPU of $1,200–$2,500/year per clinic and 70% gross margins, making recurring fees steadier than ad income.

So‑Young’s revenues: ads (RPM $8–$12 in 2024; clinics’ CAC −22% vs offline), commissions (15% take rate; RMB 420M in 2024; higher on surgeries), SaaS subscriptions (ARPU $1,200–$2,500/yr; 70% gross margin typical), B2B device/injectable sales (margins devices 12–18%, injectables 20–30%; reorder +25% YoY), and paid trainings (avg fee $500–$2,000; 2,000 attendees × $750 = $1.5M ARR example).